Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9415)	3/29/1999 3:25:00 PM
From: Edscharp	Read Replies (1) \| Respond to of 17367

Hot off the Press! March 25th issue of MTSL "We continue to wait patiently for the conclusion of the pivotal Phase III trial of XOMA's Neuprex for meningococcemia. We want to strongly reiterate that the DSMB's recommending continuing enrollment is not a negative. Rather, we interpret this as a positive. There were absolutely no safety concerns, and enrolling more patients will increase the statistical power of the trial. More often than not, pivotal testing takes longer than expected. When companies release news earlier than expected, it is more likely to be negative than it is positive. We are quite content waiting a little while longer if it increases the chances of the results turning out to be significantly positive. XOMA is a buy under $4."